四君寿胎汤改善地中海贫血孕妇贫血状况的研究

doi:10.3969/j.issn.1000-8535.2021.05.003

摘要/Abstract

摘要： 目的探讨四君寿胎汤对地中海贫血孕妇贫血状况的改善效果,以期指导地中海贫血孕妇的中药治疗。方法选择2019年5月—2020年10月期间我院诊治的200例地中海贫血孕妇,根据随机数字表法将其分为两组,观察组与对照组,各100例,观察组患者给予四君寿胎汤,1剂/d,连续治疗3个月,对照组患者给与安慰剂,1剂/d,连续治疗3个月;治疗前、治疗3个月后,比较两组血液检测指标[血红蛋白(HGB)、红细胞(RBC)、红细胞比容(HCT)、平均红细胞体积(MCV)、平均血红蛋白含量(MCH)]、中医症候积分、肝肾指标[谷丙转氨酶(ALT)、谷草转氨酶(AST)、肌酐(Cre)、尿素(ure)、总胆汁酸(TBA)],记录两组孕妇妊娠结局、新生儿情况并比较。结果治疗前,两组HGB、RBC、HCT、MCV、MCH比较,差异无统计学意义(P＞0.05);治疗3个月后,两组均升高,且观察组高于对照组(P＜0.05);治疗前,两组食少纳呆、体倦乏力、食后或午后腹胀、大便异常症候积分比较,差异无统计学意义(P＞0.05);治疗结束后,两组症候积分均较治疗前降低,且观察组低于对照组,差异有统计学意义(P＜0.05);治疗前后,两组ALT、AST、TBA、Cre、Ure差异无统计学意义(P＞0.05)。两组胎儿宫内窘迫、宫内生长受限发生率、产妇产后出血率比较,观察组较对照组发生率低,但差异无统计学意义(P＞0.05)。观察组早产发生率较对照组明显下降,差异有统计学意义(P＜0.05);观察组孕妇分娩孕周大于对照组,剖宫产率低于对照组,差异有统计学意义(P＜0.05);两组新生儿窒息率、转PICU率比较,差异无统计学意义(P＞0.05);观察组新生儿出生体重、HGB高于对照组(P＜0.05)。结论四君寿胎可以改善地中海贫血孕妇的整体贫血状况,对肝肾功能无不良影响,中医证候得到改善,且有利于减少早产发生风险,降低剖宫产率,改善新生儿情况。

关键词: 地中海贫血, 孕妇, 四君寿胎汤, 贫血, 早产

Abstract: Objective To investigate effect of Sijun Shoutai decoction in improving anemia status of pregnant women with thalassemia, and to guide the Chinese medicine treatment of thalassemia in pregnant women in the future. Methods Two hundred pregnant women with thalassemia who were diagnosed in the hospital from May 2019 to October 2020 were divided into observation group and control group randomly, with 100 cases in each group. The observation group was treated with Sijun Shoutai decoction,1 dose/d, with continuous treatment for 3 months. The control group was given placebo,1 dose/d, with continuous treatment for 3 months. The indicators of blood test [hemoglobin (HGB), red blood cell (RBC), hematocrit value (HCT), mean corpuscular volume (MCV), mean corpuscular hemoglobin (MCH)], TCM symptom scores, hepatic and renal indicators [alanine aminotransferase (ALT), aspartate aminotransferase (AST), creatinine (Cre), urea (Ure), total bile acid (TBA)] were compared between the two groups before and after treatment for 3 months. The maternal pregnancy outcome and neonatal condition in the two groups were recorded and compared. Results There were no statistical difference in the HGB, RBC, HCT, MCV and MCH between the two groups before treatment (P>0.05); after 3 months the indicators above of two groups increased, and those in observation group were higher than those in control group (P<0.05). There were no statistical differences in the symptom scores of poor appetite, fatigue, abdominal distension after eating or after noon and fecal abnormalities between the two groups before treatment (P<0.05). The levels of ALT, AST and TBA in the two groups decreased after treatment for 3 months, while the Cre and Ure increased, but the differences were not statistically significant (P>0.05). There were no statistical differences in the rates of intrauterine fetal distress, intrauterine growth restriction, and postpartum hemorrhage between the two groups (P>0.05), though the results of observation group were lower than control group.The rate of premature birth was lower than that of control group(P<0.05) ; the gestational week of observation group was more than control group, and the cesarean section rate of observation group was lower than that of control group (P<0.05). There were no statistical differences in the rates of neonatal asphyxia and transfering to PICU between the two groups (P>0.05); the neonatal birth weight and HGB in observation group were higher than those in control group (P<0.05). Conclusion Sijun Shoutai decoction in the treatment of pregnant women with thalassemia can improve anemia status, with no adverse effect on liver or kidney function, improve TCM syndrome, reduce the risk of premature birth,reduce the rate of cesarean,and improve the neonatal condition.

Key words: thalassemia, pregnant women, Sijun Shoutai decoction, anemia, premature delivery

侯明敏, 彭静, 温济英, 张丽. 四君寿胎汤改善地中海贫血孕妇贫血状况的研究[J]. 广州医药, 2021, 52(5): 14-19.

HOU Mingmin, PENG Jing, WEN Jiying, ZHANG Li. Study on Sijun Shoutai decoction in improving the anemia status of pregnant women with thalassemia[J]. Guangzhou Medical Journal, 2021, 52(5): 14-19.

参考文献

[1] SALAH N B,BOU-FAKHREDIN R,MELLOULI F,et al. Revisiting beta thalassemia intermedia: past, present, and future prospects[J]. Hematology,2017,22(10):607-616.
[2] SIRI-ANGKUL N,CHATTIPAKORN S C,Chattipakorn N.Diagnosis and treatment of cardiac iron overload in transfusion-dependent thalassemia patients[J].Expert Rev Hematol,2018,11(6):471-479.
[3] ANU K,NISHAM P,ANUP D,et al. Second hematopoietic stem cell transplant for thalassemia major:improved clinical outcomes with a treosulfan-based conditioning regimen[J].Biol Blood Marrow Transplant,2018,24(1):103-108.
[4] 程艳玲,吴志奎,张新华,等.地中海贫血不同类型与基因型及肾虚证候的关系[J].中医杂志,2015,56(5):414-417.
[5] 杨晓亮,兰炯采,胡雪,等.中医药促进红细胞与血小板再生在输血医学中的应用与研究进展[J].临床输血与检验,2019,21(3):252-256.
[6] 刘琳,李岩.四君子汤对胃肠道药理作用的研究进展[J].医学综述,2019,25(5):990-994.
[7] 郑筱萸.中药新药临床研究指导原则[M].北京:中国医药科技出版社,2002:361-382.
[8] 张之南.血液病诊断及疗效标准(第3版)[M].天津:天津科技出版社,1991:48-49.
[9] 臧传鑫,张婷婷,赵文歌,等.自拟固冲汤联合福乃得治疗冲任不固型缺铁性贫血临床观察[J].广州中医药大学学报,2018,35(1):13-18.
[10] 沈雪华,蔡艳悦.补血助孕养胎汤合多糖铁复合物胶囊治疗妊娠贫血效果分析[J].中国中医药科技,2017,24(6):800-801.
[11] 潘玥,葛会生,陈红.妊娠合并轻型地中海贫血补铁治疗的临床探讨[J].中国计划生育和妇产科,2019(6):56-59.
[12] 齐晓霞,万晓燕,王波,等.四君子汤治疗功能性消化不良的临床疗效分析[J].现代生物医学进展,2017,17(19):3734-3737.
[13] 刘巧玉,张水堂,李盛强等.四君子汤联合重组人类促红细胞生成素治疗早产儿贫血95例[J].中国中西医结合杂志,2010,30(9):995-996.
[14] 陈剑旭.四君子汤联合补铁法治疗缺铁性贫血的效果观察[J].中西医结合心血管病杂志,2016,4(25):154-155.
[15] 刘华,韦炳华,马红霞.菟丝子黄酮对流产大鼠模型母胎免疫平衡因子的影响[J].世界中西医结合杂志,2011,6(10):14-18.
[16] 刘二伟,吴帅,樊官伟.川续断化学成分及药理作用研究进展[J]. 中华中医药学刊,2010,28(7):1421-1423.
[17] 郜洁,余庆英,朱玲,等.基于中医传承系统探讨罗颂平孕前运用中药防治复发性流产的用药规律[J].广州中医药大学学报,2018,35(6):1107-1111.
[18] 赖立,王彩,陈德娟.脾肾亏虚型早期先兆流产患者应用寿胎丸加减方治疗对其妊娠结局的影响[J].四川中医,2020,38(9):158-161.
[19] 韦良家,刘顺,黄东萍,等.孕妇血红蛋白浓度与早产关联强度剂量反应关系[J].中华流行病学杂志,2019,40(4):471-474.
[20] 赵娜.妊娠期缺铁性贫血发病的危险因素及对妊娠结局的影响[J].中国妇幼保健,2021,36(5):1139-1141.
[21] 严荔煌,邢丽莉,王淼.产科早期新生儿贫血的相关因素分析[J].中国妇产科临床杂志,2020,21(1):158-161.
[22] 苏成杰,潘春燕,李洁琼.新生儿贫血危险因素的单因素与多元Logistic回归模型分析[J].实用临床医药杂志,2017,21(9):218-219.